Resurgent and delayed malaria.
Delayed malaria
Immunity
Malaria
Rebound malaria
Resurgent malaria
Journal
Malaria journal
ISSN: 1475-2875
Titre abrégé: Malar J
Pays: England
ID NLM: 101139802
Informations de publication
Date de publication:
09 Mar 2022
09 Mar 2022
Historique:
received:
10
11
2021
accepted:
22
02
2022
entrez:
10
3
2022
pubmed:
11
3
2022
medline:
12
3
2022
Statut:
epublish
Résumé
The populations of moderate or highly malaria endemic areas gradually acquire some immunity to malaria as a result of repeated exposure to the infection. When this exposure is reduced as a result of effective malaria control measures, subjects who benefitted from the intervention may consequently be at increased risk of malaria if the intervention is withdrawn, especially if this is done abruptly, and an effective malaria vector remains. There have been many examples of this occurring in the past, a phenomenon often termed 'rebound malaria', with the incidence of malaria rebounding to the level present before the intervention was introduced. Because the main clinical burden of malaria in areas with a high level of malaria transmission is in young children, malaria control efforts have, in recent decades, focussed on this group, with substantial success being obtained with interventions such as insecticide treated mosquito nets, chemoprevention and, most recently, malaria vaccines. These are interventions whose administration may not be sustained. This has led to concerns that in these circumstances, the overall burden of malaria in children may not be reduced but just delayed, with the main period of risk being in the period shortly after the intervention is no longer given. Although dependent on the same underlying process as classical 'resurgent' malaria, it may be helpful to differentiate the two conditions, describing the later as 'delayed malaria'. In this paper, some of the evidence that delayed malaria occurs is discussed and potential measures for reducing its impact are suggested.
Identifiants
pubmed: 35264158
doi: 10.1186/s12936-022-04098-6
pii: 10.1186/s12936-022-04098-6
pmc: PMC8905818
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
77Subventions
Organisme : Medical Research Council
ID : MR/P006876/1
Pays : United Kingdom
Organisme : European and Developing Countries Clinical Trials Partnership
ID : TMA2019SFP-2834
Organisme : PATH MVI
ID : CVIA083
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 212176
Pays : United Kingdom
Informations de copyright
© 2022. The Author(s).
Références
PLoS Med. 2007 Jul 31;4(7):e242
pubmed: 17676985
N Engl J Med. 2022 Feb 3;386(5):428-436
pubmed: 35108469
Malar J. 2012 Apr 24;11:122
pubmed: 22531245
Clin Infect Dis. 2017 Aug 01;65(3):453-460
pubmed: 28369387
Trans R Soc Trop Med Hyg. 1995 Nov-Dec;89(6):629-33
pubmed: 8594677
Lancet. 1997 Sep 20;350(9081):844-50
pubmed: 9310602
Lancet Infect Dis. 2019 Aug;19(8):790-791
pubmed: 31300332
Science. 2021 Aug 20;373(6557):926-931
pubmed: 34413238
Nat Commun. 2021 May 11;12(1):2635
pubmed: 33976132
Lancet Infect Dis. 2019 Sep;19(9):962-972
pubmed: 31307883
Lancet. 2005 Apr 23-29;365(9469):1481-3
pubmed: 15850632
Lancet. 1988 May 21;1(8595):1121-7
pubmed: 2896957
Lancet. 2021 May 15;397(10287):1809-1818
pubmed: 33964223
BMC Med. 2022 Jan 27;20(1):28
pubmed: 35081974
Bull World Health Organ. 2004 Feb;82(2):85-91
pubmed: 15042229
PLoS One. 2011;6(8):e23391
pubmed: 21858097
Lancet Infect Dis. 2019 Aug;19(8):821-832
pubmed: 31300331
JAMA. 2004 Jun 2;291(21):2571-80
pubmed: 15173148
Trans R Soc Trop Med Hyg. 2002 Nov-Dec;96(6):597-9
pubmed: 12625130
Hum Vaccin Immunother. 2019;15(10):2386-2398
pubmed: 31012786
PLoS One. 2011;6(8):e23390
pubmed: 21858096
Malar J. 2014 Feb 18;13:59
pubmed: 24548783